• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

    3/18/25 7:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email

    – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 –

    – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028 –

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates.

    "Recent milestones – including Breakthrough Therapy Designation, positive data supporting our Phase 3 dosing regimen and global regulatory alignment – have catalyzed the Dravet community and put us on track to initiate EMPEROR in the second quarter," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "The potential of zorevunersen to change the course of Dravet syndrome by addressing its underlying cause is becoming increasingly recognized. Our recent collaboration with Biogen brings complementary expertise in neurology and the global commercialization of high-value medicines for rare genetic diseases – expertise that will help us deliver faster for patients and maximize value. With a strong financial position, we are well-capitalized to advance through Phase 3 and prepare for launch readiness."

    Recent Program Highlights and Additional Corporate Updates

    • Separately today, the Company announced that Dr. Edward M. Kaye has decided to step down as Chief Executive Officer of Stoke Therapeutics. After seven years of successful leadership and taking the company from a startup to a late-stage clinical development company, Dr. Kaye will transition to an advisory role and continue to serve as a Director.
    • In February, the Company entered into a collaboration with Biogen to develop and commercialize zorevunersen for the treatment of Dravet syndrome. The Company retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.
    • In January, the Company announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following successful alignment with regulatory agencies in the United States, Europe, and Japan.
    • In December, the Company shared new positive data from the open-label extension (OLE) studies of zorevunersen in children and adolescents with Dravet syndrome at American Epilepsy Society (AES) 2024 Annual Meeting.
    • In December, the Company announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene.

    Year End 2024 Financial Results

    • As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities, which, along with the $165 million upfront payment received in March 2025 and other eligible cash flows from the Biogen collaboration, we anticipate will fund operations to mid-2028.
    • Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2024 was $36.6 million, compared to $8.8 million, for the year ended December 31, 2023.
    • Net loss for the year ended December 31, 2024 was $89.0 million, or $1.65 per share, compared to $104.7 million, or $2.38 per share for 2023.
    • Research and development expenses for the year ended December 31, 2024 were $89.1 million, compared to $82.2 million for 2023.
    • General and administrative expenses for the year ended December 31, 2024 were $48.8 million, compared to $41.3 million for 2023.
    • The increase in operating expenses for the year ended December 31, 2024 compared to the same period in 2023 primarily relates to increases in costs associated with personnel, third party contracts, consulting, facilities and other costs associated with development activities for zorevunersen and STK-002, research on additional therapeutics and growing a public corporation.

    Fourth Quarter 2024 Financial Results

    • Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended December 31, 2024 was $22.6 million, compared to $2.8 million for the same period in 2023.
    • Net loss for the three months ended December 31, 2024 was $10.5 million, or $0.18 per share, compared to $27.0 million, or $0.60 per share, for the same period in 2023.
    • Research and development expenses for the three months ended December 31, 2024 were $23.4 million, compared to $21.8 million for the same period in 2023.
    • General and administrative expenses for the three months ended December 31, 2024 were $12.8 million, compared to $10.6 million for the same period in 2023.
    • The increase in operating expenses for the three months ended December 31, 2024 compared to the same period in 2023 primarily relates to increases in costs associated with personnel, third party contracts, consulting, facilities and other costs associated with development activities for zorevunersen and STK-002, research on additional therapeutics and growing a public corporation.

    About Dravet Syndrome

    Dravet syndrome is a severe developmental and epileptic encephalopathy characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. More than 90 percent of patients continue to experience seizures despite treatment with the best available anti-seizure medicines. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S., UK, EU-4 and Japan.

    About Zorevunersen

    Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing NaV1.1 protein production in brain cells from the non-mutated (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition, and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene.

    About Stoke Therapeutics

    Stoke Therapeutics (NASDAQ:STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company's proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the receipt of potential cashflows under the collaboration with Biogen; the design, timing and results of the Phase 3 EMPEROR study; the timing and expected progress of regulatory filings and regulatory decisions; the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the Company's cash runway; and the expectations regarding the collaborations. Statements including words such as "anticipate," "expect," "plan," "will," or "may" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, the Company would not obtain the anticipated financial or other benefits; the possibility that the Company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company's ability to protect its intellectual property; the Company's ability to fund development activities and achieve development goals through mid-2028; and the other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

    Financial Tables Follow

    Stoke Therapeutics, Inc. and subsidiary

    Consolidated balance sheets

    (in thousands, except share and per share amounts)
     
    As of December 31,

    2024

    2023

    Assets
    Current assets:
    Cash and cash equivalents

    $

    127,983

     

    $

    191,442

     

    Marketable securities - short term

     

    88,916

     

     

    9,952

     

    Prepaid expenses

     

    11,117

     

     

    11,320

     

    Other current assets

     

    3,965

     

     

    2,561

     

    Restricted cash - short term

     

    75

     

     

    —

     

    Interest receivable

     

    700

     

     

    64

     

    Total current assets

    $

    232,756

     

    $

    215,339

     

    Restricted cash - long term

     

    721

     

     

    569

     

    Operating lease right-of-use assets

     

    4,345

     

     

    6,611

     

    Marketable securities - long term

     

    29,824

     

     

    —

     

    Property and equipment, net

     

    3,909

     

     

    5,823

     

    Total assets

    $

    271,555

     

    $

    228,342

     

    Liabilities and stockholders' equity
    Current liabilities:
    Accounts payable

    $

    2,498

     

    $

    1,695

     

    Accrued and other current liabilities

     

    18,567

     

     

    13,815

     

    Deferred revenue - current portion

    18,991

    15,309

     
    Total current liabilities

    $

    40,056

     

    $

    30,819

     

    Deferred revenue - net of current portion

     

    —

     

     

    33,074

     

    Other long term liabilities

     

    2,478

     

     

    4,884

     

    Total long term liabilities

    $

    2,478

     

    $

    37,958

     

    Total liabilities

    $

    42,534

     

    $

    68,777

     

    Commitments and contingencies
    Stockholders' equity
    Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 54,032,826 and 45,918,233 shares issued and outstanding as of December 31, 2024 and 2023, respectively

     

    5

     

     

    5

     

    Additional paid-in capital

     

    719,997

     

     

    561,433

     

    Accumulated other comprehensive loss

     

    (151

    )

     

    (24

    )

    Accumulated deficit

     

    (490,830

    )

     

    (401,849

    )

    Total stockholders' equity

    $

    229,021

     

    $

    159,565

     

    Total liabilities and stockholders' equity

    $

    271,555

     

    $

    228,342

    Stoke Therapeutics, Inc. and subsidiary

    Consolidated statements of operations and comprehensive loss

    (in thousands, except share and per share amounts)
     
    Three Months Ended

    December 31,

    (unaudited)
    Year Ended

    December 31,

    2024

    2023

    2024

    2023

    Revenue

    $

    22,614

     

    $

    2,801

     

    $

    36,555

     

    $

    8,780

     

    Operating expenses:
    Research and development

     

    23,424

     

     

    21,778

     

     

    89,133

     

     

    82,231

     

    General and administrative

     

    12,844

     

     

    10,610

     

     

    48,794

     

     

    41,322

     

    Total operating expenses

     

    36,268

     

     

    32,388

     

     

    137,927

     

     

    123,553

     

    Loss from operations

     

    (13,654

    )

     

    (29,587

    )

     

    (101,372

    )

     

    (114,773

    )

    Other income (expense):
    Interest income (expense), net

     

    2,971

     

     

    2,587

     

     

    12,638

     

     

    9,908

     

    Other income (expense), net

     

    200

     

     

    42

     

     

    (247

    )

     

    166

     

    Total other income (expense)

     

    3,171

     

     

    2,629

     

     

    12,391

     

     

    10,074

     

    Net loss

    $

    (10,483

    )

    $

    (26,958

    )

    $

    (88,981

    )

    $

    (104,699

    )

    Net loss per share—basic and diluted

    $

    (0.18

    )

    $

    (0.60

    )

    $

    (1.65

    )

    $

    (2.38

    )

    Weighted average common shares outstanding—basic and diluted

     

    57,029,296

     

     

    44,958,894

     

     

    54,008,883

     

     

    43,994,862

     

    Comprehensive loss:
    Net loss

    $

    (10,483

    )

    $

    (26,958

    )

    $

    (88,981

    )

    $

    (104,699

    )

    Other comprehensive loss:
    Unrealized gain (loss) on marketable securities

     

    (317

    )

     

    122

     

     

    (127

    )

     

    1,151

     

    Total other comprehensive gain (loss)

    $

    (317

    )

    $

    122

     

    $

    (127

    )

    $

    1,151

     

    Comprehensive loss

    $

    (10,800

    )

    $

    (26,836

    )

    $

    (89,108

    )

    $

    (103,548

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250318007984/en/

    Stoke Media & Investor Contacts:

    Dawn Kalmar

    Chief Communications Officer

    [email protected]

    781-303-8302

    Doug Snow

    Director, Communications & Investor Relations

    [email protected]

    508-642-6485

    Get the next $STOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    7/25/2023Outperform → Market Perform
    TD Cowen
    5/1/2023$9.00 → $12.00Underperform → Neutral
    BofA Securities
    4/26/2023$24.00Buy
    Canaccord Genuity
    1/6/2023$22.00 → $9.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:45 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke The

      4/1/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028 – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syn

      3/18/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Announces CEO Transition

      Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Directors Initiates Search for Permanent Chief Executive Officer Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Offi

      3/18/25 6:58:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:58 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Stoke Therapeutics Inc.

      SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 4:24:49 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:12 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

      – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

      9/4/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

      – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou

      4/17/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Ian Smith to its Board of Directors

      – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div

      9/20/23 4:30:00 PM ET
      $FHTX
      $SLDB
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Ticho Barry sold $266,953 worth of shares (26,631 units at $10.02), decreasing direct ownership by 44% to 33,998 units (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      5/5/25 4:08:50 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levin Arthur A converted options into 1,210 shares (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      4/2/25 4:03:15 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim CEO Smith Ian F

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      3/20/25 6:19:44 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Stoke Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00

      12/20/24 7:51:37 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Stoke Therapeutics with a new price target

      Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00

      10/14/24 7:42:47 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics upgraded by TD Cowen

      TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform

      3/26/24 8:09:24 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    SEC Filings

    See more
    • SEC Form 144 filed by Stoke Therapeutics Inc.

      144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

      5/1/25 4:45:41 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Stoke Therapeutics Inc.

      DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:06:17 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Stoke Therapeutics Inc.

      DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:05:27 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

      – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR – – One-year study of zorevunersen will evaluate reductions in major motor seizure frequency as well as improvements in behavior and cognition in children and adolescents ages 2 to <18 years old – – FDA Breakthrough Therapy designation positions zorevunersen on efficient development path; Company plans to start Phase 3 in mid-2025 – – Webcast and conference call for analysts and investors at 8:00AM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein

      1/7/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

      Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join th

      1/6/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care